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Abstract: Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma 
glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the 
urine (glucosuria) has transformed what was once solely regarded as an adverse facet of 
diabetes into a potential novel therapeutic strategy. Glucosuria leads to weight loss, due to a 
reduction in calories, which is thought to rehabilitate insulin sensitivity, at least partially. By 
acting independently of insulin action or secretion, dapagliflozin appears to avert or minimize 
two key barriers to optimal glycemic control: hypoglycemia and weight gain. From the clinical 
studies conducted thus far in patients with type 2 diabetes, dapagliflozin significantly decreases 
HbA1c (by ∼0.5%–1%, from a baseline of 8%–9%), as well as body weight (∼2–3 kg), without 
increased risk of hypoglycemia. Dapagliflozin thus represents a paradigm shift in the treatment 
of diabetes. While long-term data on safety and efficacy are forthcoming, the results published 
to date suggest that this agent has the potential to be another option in the treatment of diabetes 
treatments. This article examines the evidence currently available on the efficacy and safety 
of dapagliflozin.
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Core evidence clinical impact summary for dapagliflozin in the treatment of 
type-2 diabetes
Outcome 
measure
Evidence Implications
Disease-
oriented 
evidence
Lowers measures such as HbA1c, fasting 
glucose, and postprandial glucose, via a 
novel mechanism – inhibition of renal 
glucose reabsorption
Weight loss without the potential for 
hypoglycemia, which could result in 
improved glycemic control without 
limiting adverse effects.
Possible greater patient acceptance due 
to being a PO agent
Patient-
oriented 
evidence
Awaiting long-term studies. Citing 
increased numbers of cases of 
bladder and breast cancer in patients 
administered dapagliflozin compared 
with control subjects, the US Food and 
Drug Administration (FDA) recently 
decided against approving this agent
Unclear at present; potential adverse 
effects, such as fungal genital infections 
and UTI, may affect patient and provider 
acceptance. Whether dapagliflozin is 
associated with the cancers that have 
raised concern is uncertain
Economic 
evidence
None available yet Currently unknown
Introduction
Although eleven distinct classes of diabetes medications are currently available, 
approximately two-thirds of patients with diabetes are not meeting their glycemic goals.1 
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The number of individuals with diabetes mellitus continues 
to escalate at epidemic rates. According to the International 
Diabetes Federation’s latest estimates in 2011, 366.2 mil-
lion persons worldwide have diabetes; with three new cases 
diagnosed around the world every ten seconds, this figure is 
projected to soar by 51% by 2030.2 In the USA, 25.8 million 
individuals are presently living with diabetes.3
Varying degrees of relative insulin deficiency and insulin 
resistance comprise the central defects in patients with type 
2 diabetes (T2DM). Excessive gluconeogenesis by the liver, 
along with diminished glucose uptake by target tissues, lead 
to fasting and postprandial hyperglycemia. This chronic 
hyperglycemia can facilitate β-cell failure in the pancreas and 
worsen insulin resistance, thus triggering a cycle of impaired 
metabolism and glucose toxicity that defines diabetes.4
Aside from multiple pathophysiological defects, other fac-
tors that impede efforts to attain glycemic goals include adverse 
effects of the currently available agents for T2DM. For instance, 
metformin can cause gastrointestinal effects, such as diarrhea 
and nausea, and, rarely, lactic acidosis; insulin or sulfonylu-
reas may produce hypoglycemia, as well as weight gain; and 
thiazolidinedione use is also associated with weight gain and 
edema.5 The incretin mimetics may cause nausea, vomiting, 
and diarrhea.6 As most current diabetes agents address insulin 
secretion or insulin action, with time, as the disease progresses, 
endogenous insulin production becomes insufficient. Exogenous 
insulin or another medication, if added, could result in further 
unwanted adverse effects. Consequently, the quest to develop 
novel therapeutic agents, without these side effects, continues.
The investigations carried out thus far on sodium-glucose 
co-transporter-2 (SGLT2) inhibitors have elucidated new 
perspectives not only on the mechanism of diabetes, but 
also on potential therapeutic applications of this knowledge. 
Historically, glucosuria – glucose excretion in the urine – has 
been viewed as a marker of metabolic decompensation and 
an adverse clinical consequence in the natural history of 
  diabetes. The kidney plays a pivotal role in glucose homeo-
stasis by regulating the reabsorption of glucose back into the 
plasma after filtration of the blood. In individuals with diabe-
tes, what was once an adaptive process becomes damaging, 
as glucose reabsorption may increase up to 20% and perpetu-
ate continued elevation in serum glucose levels. Blocking 
this process and, thus, facilitating glucose to be excreted in 
the urine, is being examined as a potential new therapeutic 
target in diabetes. Thus, effecting glycosuria for treating 
diabetes is a paradigm shift. As SGLT2 inhibitors target 
the renal handling of glucose and would not be expected to 
Figure 1 Normal glucose homeostasis. 
Notes: This figure depicts the hormonal interactions that are key in normal glucose 
homeostasis. Normal fasting glucose homeostasis involves the regulation of glucose 
utilization and production, as well as the filtration and reabsorption of glucose by the 
kidney. Under basal conditions, glucose uptake by the tissues is matched by glucose pro-
duction from the liver, which enables precise regulation of glucose at a very fixed level.
Copyright © 2010, Nature Pub. Group. Adapted from DeFronzo RA. Pharmacologic 
therapy  for  type  2  diabetes  mellitus.  Ann  Intern  Med.  1999;131(4):281–303.34 
Reproduced with permission from Chao EC, Henry RR. SGLT2 inhibition – a novel 
strategy for diabetes treatment. Nat Rev Drug Discovery. 2010;9(7):551–559.8
cause hypoglycemia – thus, acting independently of insulin 
resistance and insulin secretion – they represent potentially 
promising novel agents in the treatment of diabetes.
By decreasing renal glucose reabsorption due to 
enhancing urinary glucose excretion, SGLT2 inhibitors 
decrease the hyperglycemia that contributes to insulin resis-
tance and diminished insulin secretion. Blockade of SGLT2 
also appears to ameliorate pathophysiological defects under-
lying T2DM other than hyperglycemia, including factors 
such as weight gain, blood pressure, and lipids. This article 
provides a brief overview of the history of the development 
and the mechanism of the action of SGLT2 inhibitors, and 
it will focus on clinical studies of dapagliflozin.
Renal glucose handling and SGLT
The role of the kidney in glucose balance has been insuf-
ficiently appreciated; however, it is no less crucial. Together 
with the liver, the kidney provides glucose during periods of 
fasting. The kidney not only contributes to gluconeogenesis 
(approximately 15–55 g per day, or 20%–25% of the glucose 
released into the circulation after an overnight fast), but also 
reabsorbs glucose (Figure 1).7
In individuals without diabetes, in the setting of a 
plasma glucose concentration of ∼90 mg/dL, essentially 
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all of the ∼180 g of glucose that is filtered per day by the 
glomeruli is reabsorbed.9 Sodium-glucose co-transporters 
(SGLTs) are the specific mediators of renal glucose reab-
sorption, with 90% of this reabsorption being facilitated by 
the isoform termed SGLT2, and the remainder by SGLT1 
(Figure 2). Found mainly in the S1 segment of the proximal 
convoluted tubule (PCT) of the kidney, SGLT2 is expressed 
almost entirely in the kidney; it is a high-capacity, low-affinity 
transporter.10 Both expression and function of SGLT2 are 
increased in patients with T2DM.11 SGLT1 is a low-capacity, 
high-affinity co-transporter located more distally, in the 
PCT’s S2 and S3 segments.10
As this filtrate passes through the proximal tubule of the 
kidney, SGLT2 transporters located on the luminal surface 
combine active transport of glucose (against a concentration 
  gradient) with that of sodium (Figure 3).12 Glucose transporters 
  (specifically, GLUT2) carry glucose into the basolateral 
aspect, or the blood, by passive transport (with a concentra-
tion gradient).
As glucose increases, reabsorption by the kidney 
continues, without any glucose being excreted, until a 
  theoretical threshold is reached (approximately 11 mmol/L 
or 200 mg/dL) (Figure 4).13 As this threshold is approached, 
the SGLTs reach saturation; once exceeded, glucose begins 
to appear in the urine. The actual threshold is somewhat 
lower, due to both anatomical and physiological variations 
among individual nephrons, such as the observation that 
not all nephrons exhibit the same threshold for reabsorption 
Figure 2 Glucose regulation by the kidneys in a non-diabetic individual.
Copyright © Nature Pub. Group. Adapted from Wright EM. Renal Na(+)-glucose 
cotransporters.  Am  J  Physiol  Renal  Physiol.  2001;280(1):F10–F18.35  Reproduced 
with permission from Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for 
diabetes treatment. Nat Rev Drug Discovery. 2010;9(7):551–559.8
Figure 3 SGLT2 mediates glucose reabsorption in the kidney and catalyzes the 
active transport of glucose (against a concentration gradient) across the luminal 
membrane, by coupling it with the downhill transport of Na+.
Notes: The inward Na+ gradient across the luminal epithelium is maintained by active 
extrusion  of  Na+  across  the  basolateral  surface  into  the  intercellular  fluid,  which 
is in equilibrium with the blood. Glucose passively diffuses out of the cell, down a 
concentration gradient, via basolateral facilitative transporters, GLUT2 (and GLUT1)   
Copyright © 2010, Nature Pub. Group.
Reproduced with permission from Chao EC, Henry RR. SGLT2 inhibition – a novel 
strategy for diabetes treatment. Nat Rev Drug Discovery. 2010;9(7):551–559.8
Figure 4 Renal glucose handling before and following inhibition of SGLT2.
Notes:  With  gradual  infusion  of  glucose,  as  the  plasma  glucose  concentration 
increases,  the  reabsorption  progressively  increases,  following  the  line  marked 
“Reabsorption”  (in  red).  At  plasma  glucose  concentrations  ,200  mg/dL,  all  the 
filtered glucose is reabsorbed, and there is no excretion. When glucose reaches 
a  threshold,  at  ∼200–250  mg/dL,  the  maximum  capacity  of  the  renal  tubule  to 
reabsorb glucose – the Tmax – is exceeded. Once past this threshold, glucose begins 
to be excreted into the urine (green line, labeled “Excretion”). The breaking point, 
however, is not abrupt. Splay, which represents glucose excretion in the urine before 
saturation (Tmax), is fully attained and is explained by some nephrons releasing glucose 
at a slightly lower threshold (some a bit higher) and the relatively low affinity of 
the Na–glucose carriers. The dotted yellow lines depict renal glucose handling after 
SGLT2 inhibition. The SGLT2 inhibitors lower the Tmax of glucose, which in turn 
increases the excretion of glucose via the kidneys. Copyright © 2010, Nature Pub. 
Group.
Reproduced with permission from Chao EC, Henry RR. SGLT2 inhibition – a novel 
strategy for diabetes treatment. Nat Rev Drug Discovery. 2010;9(7):551–559.8
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and excretion. This difference between the theoretical and 
actual thresholds is termed “splay,” and it is depicted as the 
curvilinear slope for both the reabsorption and excretion 
curves. Inhibition of SGLT is due to lowering of the TmG, or 
decreasing the excretion threshold, or both.
Familial renal glucosuria
Mutations in the gene encoding SGLT2 result in an 
autosomal genetic disorder, familial renal glucosuria 
(FRG). The transmission of this rare disease is thought 
to be co-dominant with incomplete penetrance. Patients 
have excreted as much as 170 g of glucose per day, are 
asymptomatic, and have no known abnormalities of 
glucose or renal function; have not demonstrated an 
increased incidence of diabetes, chronic kidney disease, or 
urinary tract infection; and have normal life expectancy.14 
Some have suggested that FRG serves as a model for 
SGLT2 inhibition. The two may not be completely similar, 
as there are immunity abnormalities that are found in 
T2DM patients, but not in those with FRG. Such impaired 
immunity may explain the potential for increased urinary 
tract and genital fungal infections in patients with T2DM 
(discussed later in this review).
Development of early SGLT  
inhibitors – phlorizin
The Greek physician Aretaeus of Cappadocia, in the sec-
ond century AD, suggested that diabetes was due to a 
derangement in the kidneys, and he postulated that polyu-
ria was a compensatory mechanism.15 The kidney’s role in 
  glucose homeostasis had been less recognized until relatively 
recently. In 1835, phlorizin was isolated from the root bark 
of the apple tree by French chemists.16 In a landmark study, 
phlorizin was   demonstrated to reverse insulin resistance and 
beta-cell   dysfunction.17 Diabetes was induced in rats that had 
undergone partial pancreatectomies. Phlorizin administration 
increased urinary glucose excretion, normalized both fasting 
and postprandial plasma glucose, and completely reversed 
glucotoxicity. Once phlorizin was discontinued, diabetes and 
its markers were restored. This and subsequent investigations 
established the concept that hyperglycemia contributes to 
insulin resistance and, thus, to the development of diabetes.
Phlorizin could not be used clinically, as its O-glycoside 
linkage rendered it susceptible to rapid degradation, and thus, 
low bioavailability.16 This compound also was a nonselective 
SGLT inhibitor; that is, it blocked both SGLT1 and SGLT2. 
SGLT1, predominantly expressed in the small intestine and 
other regions, such as the kidney, transports both glucose and 
galactose. Diminished absorption of glucose and galactose leads 
to potentially severe dehydration and diarrhea.16 Phloretin is a 
breakdown product of phlorizin, and it inhibits multiple GLUTs, 
with the consequence of impairment of glucose transport.
Dapagliflozin (BMS-512148; AstraZeneca, Bristol–
Myers Squibb) is the SGLT2 inhibitor that has progressed the 
furthest in development. This agent has a C-glycoside linkage 
that confers greater stability than its predecessor compounds, 
allowing once-daily dosing. The half-life is approximately 
17 hours, and maximal plasma concentration is reached in 
about two hours.18 Dapagliflozin is 1200-fold more specific 
for SGLT2 than for SGLT1.19
Improved plasma glucose and HbA1c
Dapagliflozin has been shown, in multiple clinical 
studies, to reduce both HbA1c and fasting plasma glucose. 
Subjects with T2DM exhibited blockade of glucose 
reabsorption that was dose-dependent for 5, 25, and 100 mg of 
dapagliflozin, which ranged from 20% to 44% over 14 days; 
  glucosuria was observed to be up to 70 g/day, which is 
  equivalent to approximately 280 cal.18 Patients with   diabetes 
uncontrolled with oral   diabetes agents for six weeks or more 
–   metformin $ 1,000 mg and/or pioglitazone $ 30 mg or 
rosiglitazone 4 mg – and on at least 12 weeks of insulin 
and at least 6 weeks of a stable insulin dose at $50 units 
daily demonstrated mean changes in HbA1c of −0.70% for 
dapagliflozin 10 mg and −0.78% for dapagliflozin 20 mg at 
twelve weeks.20
Dapagliflozin administration led to significant placebo-
adjusted reductions in HbA1c of −0.58%, −0.77%, and −0.89% 
in 485 newly diagnosed, treatment-naïve T2DM patients 
  controlled by diet and exercise administered 2.5, 5, and 
10 mg of dapagliflozin, respectively. The HbA1c change in 
the placebo group was −0.23%.21 Dapagliflozin 5 and 10 mg 
daily administered to a subgroup of 74 subjects with HbA1c 
between 10.1% and 12.0% lowered this measure by 2.88% 
and 2.66%, respectively. When added to metformin, HbA1c 
decreased −0.54% in subjects on dapagliflozin. The first large 
clinical trial of dapagliflozin examined 534 patients with 
T2DM, inadequately controlled on metformin.21 At week 24, 
dapagliflozin in doses of 2.5, 5, and 10 mg per day yielded a 
decline in the mean HbA1c of −0.67%, −0.70%, and −0.84%; 
the reduction was −0.30% in the placebo group. A 24-week 
trial of 597 patients with T2DM uncontrolled on sulfonylurea 
monotherapy revealed decreases in HbA1c across all dose 
groups; placebo: −0.13%; 2.5 mg: −0.58%; 5 mg: −0.63%; 
and 10 mg: −0.82%.23 Dapagliflozin was demonstrated to be 
noninferior to glipizide, as an add-on agent to metformin; 
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both groups’ HbA1c declined by −0.52% at 52 weeks.24 What 
was notable was the path taken – the glipizide + metformin 
group declined more sharply, but it gradually increased dur-
ing the maintenance period. The dapagliflozin + metformin 
cohort experienced a slower and less steep, though sustained, 
decline. A trial compared 151 subjects with diabetes of one 
year duration (early stage) with 58 subjects with diabetes 
for a mean of 11.1 years (late stage).25 These patients were 
randomized into groups of dapagliflozin 10 or 20 mg daily 
for 12 weeks. The HbA1c in the late stage group decreased 
0.5%–0.7%, from 8.4%, and the early stage cohort declined 
0.6%–0.8%, from 7.6%. The similar degree of reduction in 
HbA1c is due to the insulin-independent mechanism of action 
of dapagliflozin.
A 24-week clinical trial was the first to investigate dapa-
gliflozin as initial monotherapy and in combination with met-
formin in treatment-naïve T2DM patients.26 Two randomized 
trials compared dapagliflozin plus metformin, dapagliflozin 
alone, and metformin alone. Study 1 dosed dapagliflozin 
at 5 mg; study 2, at 10 mg. Significantly greater reductions 
in HbA1c were seen with combination therapy compared 
with monotherapy in both studies: in study 1: −2.05% 
for dapagliflozin + metformin; −1.19% for dapagliflozin; 
and −1.35% for metformin. Study 2 demonstrated −1.98% 
for dapagliflozin + metformin, −1.45% for dapagliflozin, 
and −1.44% for metformin.
Wilding et al examined the effect of dapagliflozin on 
glycemic control in patients with T2DM uncontrolled on 
insulin, with or without oral antidiabetic medications.27 
These subjects, and patients previously taking pioglita-
zone $ 30 mg, were subsequently randomized into groups 
of dapagliflozin 5 mg, dapagliflozin 10 mg daily, or placebo 
daily, along with open-label pioglitazone. The mean decrease 
in HbA1c from baseline was −0.82% and −0.97% for the dapa-
gliflozin 5 mg and 10 mg groups, respectively. The decline 
in those on placebo was −0.42%.
T2DM patients who were treatment-naïve, or those on 
metformin, sulfonylurea, or a thiazolidinedione, were admin-
istered pioglitazone for ten weeks.28 In subjects administered 
dapagliflozin 2.5 mg daily, mean HbA1c decreased by −0.79% 
to −0.96%; by −0.49% for those on 5 mg daily; and −0.57% 
for the 10 mg group (the reduction for the placebo cohort 
was −0.39%).
Reduced total body weight
Dapagliflozin, whether given as monotherapy or when 
added to other agents, has resulted in statistically significant 
weight loss. As monotherapy, dapagliflozin caused weight loss 
from −2.7 to −3.2 kg at 24 weeks.21 Statistically significant, 
dose-dependent reductions were observed on day 13 of a 
two-week study of 47 patients with T2DM: −18.8, −28.8, 
and −38.7 mg/dL for the 5 mg (−11.7%), 25 mg (−13.3%), 
and 100 mg (−21.8%) doses, respectively, as compared 
with the placebo group.18 When administered along with 
  metformin, weight loss persisted over two years: −2.8 kg 
  compared with −0.7 kg for the placebo. When added to 
subjects who were suboptimally controlled on high doses 
of insulin and oral antidiabetic agents, the mean changes 
in total body weight were −4.5 kg for those on 10 mg of 
dapagliflozin and −4.3 kg for those on 20 mg.20 The change 
for the placebo group was −1.9 kg. Bailey et al found −0.9 kg 
for the subjects on placebo, −2.2 kg for dapagliflozin 2.5 mg, 
−3.0 kg for 5 mg, and −2.9 kg for 10 mg.22 In the Nauck 
et al study, dapagliflozin led to weight loss of −3.2 kg with 
dapagliflozin 2.5 mg versus weight gain (1.2 kg; P , 0.0001) 
with glipizide 5 mg.24 Strojek et al detected body weight 
reductions in the placebo, 2.5 mg, 5 mg, and 10 mg groups 
of −0.72 kg, −1.18 kg, −1.56 kg, and −2.26 kg, respectively.23 
A study of 182 patients with T2DM suboptimally controlled 
on metformin examined the effect of dapagliflozin 10 mg 
versus placebo on total body weight. At week 24, the placebo-
corrected change in TBW was −2.08 kg [95% confidence 
interval (CI): −2.84 to −1.31; P , 0.0001].29 The 24-week 
study comparing dapagliflozin, metformin XR, or both, as 
initial therapy, revealed −2.66 kg, −2.61 kg, −1.29 kg in the 
dapagliflozin + metformin, dapagliflozin, and metformin 
groups, respectively in study 1. Study 2 reductions 
were −3.33 kg, −2.73 kg, and −1.36 kg, respectively.26 
In the clinical trial by Wilding et al of patients on insulin, 
body weight decreased by −0.92 to −1.61 kg with 
dapagliflozin and increased by 0.43 kg with the placebo in 
the 2.5 mg group, −1.42 kg in the 5 mg group, and −2.04 kg 
in the 10 mg group.27 The study by Ferrannini et al21 was an 
exception, in that the mean body weight reductions did not 
reach statistical significance, although they were higher than 
with the placebo at all doses. The subjects in this study were 
treatment-naïve, and their hyperglycemia was not controlled 
by lifestyle-only changes, which is a key difference from 
most of the other clinical trials on dapagliflozin to date. The 
Zhang et al25 and Henry et al26 studies are exceptions.
Reduced fasting glucose
Dose-dependent decreases in fasting plasma glucose (FPG) 
have been observed. Mean changes in FPG from baseline 
FPG were −18.8, −28.8, and −38.7 mg/dL in the 5 mg, 25 mg, 
and 100 mg dose groups, respectively. In another study, they 
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were +17.8, +2.4, and −9.6 mg/dL (placebo, 10 mg dapagliflozin, 
and 20 mg dapagliflozin, respectively).20   Ferrannini et al found 
FPG reductions of −15.2, −24.1, −28.8, and −4.1 mg/dL for 
doses of 2.5 mg, 5 mg, 10 mg, and placebo, respectively.21 In 
the study by Strojek et al, FPG decreased by −2.0, −16.8, −21.3, 
and −28.5 mg/dL in the placebo and dapagliflozin 2.5 mg, 
5 mg, and 10 mg dose groups, respectively.23 FPG was not a 
primary or secondary endpoint for the Nauck et al trial.24 In the 
Henry et al study 1 cohort, FPG decreased by −61.1, −42.0, 
−33.5 mg/dL in the dapagliflozin + metformin, dapagliflozin, 
and metformin groups, respectively. In study 2, the reductions 
in FPG were −60.4, −46.5, and −34.8 mg/dL, respectively.26
Effect on fat mass and regional  
adipose tissue distribution
Bolinder et al also examined the secondary endpoints of 
waist circumference, which decreased −1.52 cm.29 Fat 
mass declined −1.48 kg; the visceral adipose tissue (VAT) 
decreased −258.4 cm3, and the subcutaneous adipose tissue 
(SAT) reduced by 184.9 cm3.
Safety
While no long-term data on adverse effects with dapagli-
flozin have yet been published, adverse events were generally 
balanced across treatment groups and were usually minor. 
No severe hypoglycemic events have been observed thus 
far; the small number of instances of hypoglycemia noted 
were self-limiting and mild.20–24 Glucosuria can potentially 
result in increased risk of genital fungal and urinary tract 
infections. Vulvovaginal infections in females and balanitis 
in males have occurred in increased numbers in subjects on 
dapagliflozin (∼8%–10%) compared with those on placebo 
(∼3%–5%).20–22 Most of these infections were mild to moder-
ate in intensity, and they either responded to medication or 
spontaneously resolved; a number of these infections were 
self-reported and could not be confirmed by microbiological 
culture testing. These adverse events rarely led to discontinu-
ation of dapagliflozin. Various clinical trials have noted a 
slight increase in the rate of UTI, up to 13% of subjects with 
T2DM who were treatment-naïve or who were suboptimally 
controlled on metformin, compared with 1.3% and 5% in 
those two groups, respectively.21,22,24
Systolic blood pressure declined by 3–5 mmHg and 
diastolic blood pressure by ∼2 mmHg with 10 mg/day dose 
of dapagliflozin.21,22 These reductions are in accord with the 
diuretic effect of this agent, and they were unaccompanied by 
greater instances of orthostatic hypotension. Data thus far have 
not shown an increased risk of cardiovascular disease.
As both glucose and sodium are co-transported, and thus are 
both inhibited, dapagliflozin may cause an elevation in urinary 
excretion of sodium. Although such transient increases in urine 
sodium have been reported, there have been no clinically sig-
nificant changes in serum sodium.18 Studies have documented 
slight increases in serum magnesium, phosphorus, hematocrit, 
and blood urea nitrogen (BUN).22,24 The elevated hematocrit 
is also consistent with the diuresis that is a property of dapa-
gliflozin. Serum creatinine did not change. Small declines in 
serum uric acid and high-sensitivity C-reactive protein have 
been seen.30 The implications of such findings are not yet 
certain; for instance, there is an association with increased 
serum uric acid and DM, renal dysfunction, and cardiovascular 
disease, although no etiologic link has been established.31,32
By a vote of nine to six, on July 19, 2011, an FDA advisory 
committee recommended against approval of dapagliflozin.33 
The panel cited concerns over reported cases of bladder 
cancer and breast cancer, as well as potential effects on the 
liver. Out of 4310 individuals who were administered dapagli-
flozin, nine total cases of bladder cancer were detected, while 
one of 1962 subjects had bladder cancer in the control group. 
(Two of the nine cases of bladder cancer in the dapagliflozin 
group and the one in the control group were reported after the 
4-month Safety Update cutoff date.) Before randomization, 
three subjects on dapagliflozin had microscopic hematuria, 
and one had trace hematuria.
Nine of 4287 patients in the dapagliflozin group were 
reported to have breast cancer; none of 1941 placebo subjects 
were found to have this cancer. Subjects were on dapagli-
flozin for a shorter duration (,1 year) than the average of 
more than 5 years suggested as sufficient for the detection 
of breast cancer.
Of five patients taking dapagliflozin who met the criteria 
for Hy’s Law (defined as an aspartate aminotransferase [AST] 
or alanine transaminase [ALT] greater than three times the 
upper limit of normal, and an increase in total bilirubin 
greater than two times the upper limit of normal), one was 
considered a “probable diagnosis of mild to moderately severe 
dapagliflozin-induced liver injury.”33 Two of those five sub-
jects had transaminitis – an AST or ALT greater than three 
times the upper limit of normal – that may have been due to 
drug-induced injury. On January 19, 2012, the FDA did not 
approve dapagliflozin. The FDA sent Complete Response Let-
ters to BMS and AstraZeneca, requesting “additional clinical 
data to allow a better assessment of the benefit–risk profile.” 
Detection bias has been proposed as a possible explanation; 
for instance, for the bladder cancer cases, there may have 
been a higher number of urinalyses conducted in the study 
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subjects. These cancer signals could indicate that neoplasms 
were developing before dapagliflozin treatment had begun. 
The number of cases does not allow one to reach conclusions 
about whether this agent is the cause of the hepatic and cancer 
events. While approval of dapagliflozin at a later date remains 
to be determined, it is clear that these signals raised concerns, 
and further studies will possibly be undertaken.
Unanswered questions
Although dapagliflozin has been studied in over 5,000 patients 
in 19 clinical trials, unresolved questions remain. Dapagli-
flozin is thought to be less effective in patients with existing 
compromised renal function: moderate impairment has been 
defined as an estimated glomerular filtration rate $ 30 and 
,60 mL/min. These subjects had the greatest number of 
adverse events of renal impairment or renal failure. How this 
agent would impact renal function in the long term is uncertain. 
Would patients and their physicians be hesitant to start a medi-
cation with the potential for fungal infections and UTI?
The literature, to date, suggests that dapagliflozin could 
serve as either monotherapy or as an add-on to metformin, 
sulfonylureas, and insulin. Dapagliflozin’s place in the treat-
ment of diabetes remains to be clarified. Studies have been 
conducted only in patients with type 2 diabetes; effects on 
those with type 1 diabetes are unknown.
Dapagliflozin causes increased urinary glucose excre-
tion, which leads to weight loss. Whether this reduction is 
attributable to fluid loss secondary to osmotic diuresis, or 
to decreased body fat due to a deficit in calories, or both, 
has been unclear. The study by Bolinder et al revealed that 
dapagliflozin significantly lowered both DEXA fat mass and 
total body weight.29 Approximately two-thirds of the weight 
decline with dapagliflozin subjects was due to fat mass reduc-
tion, compared with half of such a loss with those randomized 
to placebo.25 These findings were associated with sustained 
elevations in urinary glucose excretion, thus lending sup-
port to caloric deficit as the main source of weight loss. The 
initial rapid decline in TBW may have been largely a result 
of fluid loss. The issue can still be considered unresolved, as 
spot urinary glucose excretion, and not 24-hour excretion, 
was measured in this study; in addition, food and fluid intake 
were not controlled.
How the FDA’s decision could impact the development 
of this class is uncertain. As dapagliflozin is a first-in-class 
agent, the companies developing other SGLT2 inhibitors, 
such as canagliflozin, may face similar concerns, and 
will possibly be able to anticipate the safety concerns and 
provide data.
Conclusion
Dapagliflozin employs a novel, insulin-independent mecha-
nism of action to promote glucosuria and, thus, loss of 
calories. This weight loss is thought to ameliorate insulin 
resistance and consequent glucotoxicity. Therefore, while 
this agent and other SGLT2 inhibitors do not directly affect 
insulin secretion or sensitivity, the impact is indirect, due to 
effects on reducing hyperglycemia. While long-term efficacy 
and safety data are pending, and questions have been raised 
from the FDA’s recent decision on dapagliflozin’s approval 
status, data from studies thus far suggest a potential role for 
this agent. The kidney is being viewed differently than it has 
been traditionally, and it is thus being utilized as a potential 
novel target for therapy.
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